(Q41144344)

English

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

scientific article published on December 1996

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 September 2017

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel (English)

1 reference

Europe PubMed Central

27 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Rixe O

1

1 reference

Europe PubMed Central

27 September 2017

Ortuzar W

2

1 reference

Europe PubMed Central

27 September 2017

Alvarez M

3

1 reference

Europe PubMed Central

27 September 2017

Parker R

4

1 reference

Europe PubMed Central

27 September 2017

Reed E

5

1 reference

Europe PubMed Central

27 September 2017

Paull K

6

1 reference

Europe PubMed Central

27 September 2017

Fojo T

7

1 reference

Europe PubMed Central

27 September 2017

language of work or name

0 references

publication date

1 December 1996

1 reference

Europe PubMed Central

27 September 2017

Biochemical Pharmacology

1 reference

Europe PubMed Central

27 September 2017

52

1 reference

Europe PubMed Central

27 September 2017

1855-1865

1 reference

Europe PubMed Central

27 September 2017

12

1 reference

Europe PubMed Central

27 September 2017

Fundamental studies with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Reversal of Cisplatin Resistance with Amphotericin B in a Non-small Cell Lung Cancer Cell Line

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Modulation ofcis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

New platinum complexes with anti-tumour activity

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Antitumor activity of l-OHP in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2981490-6

7 January 2021

Identifiers

10.1016/S0006-2952(97)81490-6

1 reference

Europe PubMed Central

27 September 2017

1 reference

Europe PubMed Central

27 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41144344&oldid=1915968469"